To study the impact of sGC signalling on SCLC cell fate, we reduced GUCY1B1 expression using two different sgRNAs targeting GUCY1B1. Cells were treated with the NO donor DETA NONOate and the impact was assessed by phosphorylation of vasodilator-stimulated phosphoprotein (pVASP) levels, an established biomarker of sGC pathway activation30. Here, VASP is linked to small cell lung carcinoma.